Abstract
The European Respiratory Society (ERS) International Congress is the largest respiratory congress and brings together leading experts in all fields of respiratory medicine and research. ERS Assembly 3 shapes the basic and translational science aspects of this congress, aiming to combine cutting-edge novel developments in basic research with novel clinical findings. In this article, we summarise a selection of the scientific highlights from the perspective of the three groups within Assembly 3. In particular, we discuss new insights into the pathophysiology of the human alveolus, novel tools in organoid development and (epi)genome editing, as well as insights from the presented abstracts on novel therapeutic targets being identified for idiopathic pulmonary fibrosis.
Abstract
The amount of basic and translational science presented at #ERSCongress is steadily increasing, showing novel cutting-edge technologies and models. http://bit.ly/2GgXIJi
Footnotes
Conflict of interest: M.Z. Nikolić has nothing to disclose.
Conflict of interest: E.M. Garrido-Martin is a member of Bristol Myers Squibb's scientific advisory board, outside the submitted work.
Conflict of interest: F.R. Greiffo has nothing to disclose.
Conflict of interest: A. Fabre has nothing to disclose.
Conflict of interest: I.H. Heijink has nothing to disclose.
Conflict of interest: A. Boots has nothing to disclose.
Conflict of interest: C.M. Greene has nothing to disclose.
Conflict of interest: P.S. Hiemstra reports research grant to his department from Boehringer Ingelheim and Galapagos, outside the submitted work.
Conflict of interest: S. Bartel reports grants and personal fees from Bencard Allergie GmbH, outside the submitted work.
Support statement: E.M. Garrido-Martin and S. Bartel are supported by a Marie Curie Post-doctoral Research Fellowship (RESPIRE3) from the European Respiratory Society and the European Union's H2020 research and innovation programme (Marie Sklodowska-Curie grant agreement No. 713406). M.Z. Nikolić is supported by a Rutherford Fund Fellowship allocated by the “Medical Research Council and the UK Regenerative Medicine Platform (MR/5005579/1)”.
- Received October 23, 2018.
- Accepted March 23, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.